FDA to Review Efgartigimod for Generalized Myasthenia Gravis
Efgartigimod, an Fc receptor antagonist, reduces disease-causing immunoglobulin G (IgG) antibodies and blocks the IgG recycling process.
Miscellaneous Neurodegenerative Disorders
Cerliponase Alfa May Slow Developmental Function Decline in CLN2 Disease
Cerliponase alfa demonstrates a slower rate of decline of developmental skills in patients with CLN2 disease compared to a natural history cohort.
Brain-Eating Amoeba Found in Tap Water of Lake Jackson, Texas
Infection can occur when Naegleria fowleri-contaminated water enters body through the nose.
Florida Teen Dies From Brain-Eating Amoeba
Naegleria fowleri can get into the brain when contaminated water enters the nose.
Enspryng, a Self-Administered Treatment for NMOSD, Gets FDA Approval
The FDA has approved Enspryng (satralizumab-mwge; Genentech) for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.
Vitamin D/Calcium Reduces Benign Paroxysmal Positional Vertigo
Annual recurrence rate reduced with vitamin D, calcium supplementation versus observation.
Nephrogenic Systemic Fibrosis Rare With Newer GBCA Exposure
Data scant on exposure to gadolinium-based contrast agents for those with acute kidney injury, risk for CKD.
Higher Doses of Deutetrabenazine Examined in Patients With Huntington Disease-Associated Chorea
Higher doses of deutetrabenazine appear to be safe and well tolerated in patients with Huntington disease who may require them to adequately control chorea, according to a recently published post-hoc analysis.
Uplizna Approved for Neuromyelitis Optica Spectrum Disorder
The FDA has approved UpliznaTM (inebilizumab-cdon; Viela Bio) for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.
Antigen-Specific Therapy for Anti-MAG Neuropathy Gets Orphan Drug Status
The FDA has granted Orphan Drug designation to PN-1007 (PPSGG; Polyneuron Pharmaceuticals) for the treatment of anti-myelin-associated glycoprotein (MAG) neuropathy.
